Valuation: Marker Therapeutics, Inc.

Market Cap 18.84M 16.38M 15.24M 14M 26.43M 1.8B 26.84M 180M 70.52M 895M 70.76M 69.2M 3B P/E 2026 *
-1.17x
P/E 2027 * -1.12x
Enterprise Value 18.84M 16.38M 15.24M 14M 26.43M 1.8B 26.84M 180M 70.52M 895M 70.76M 69.2M 3B EV / Sales 2026 *
6.66x
EV / Sales 2027 * 0.94x
Free-Float
94.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Marker Therapeutics, Inc.

1 day+0.89%
1 week-7.38%
1 month-22.07%
3 months-22.60%
6 months-29.38%
Current year-24.16%
1 week 1.05
Extreme 1.05
1.25
1 month 1.05
Extreme 1.05
1.72
Current year 1.05
Extreme 1.05
2.46
1 year 0.81
Extreme 0.8099
2.46
3 years 0.81
Extreme 0.8099
6.96
5 years 0.67
Extreme 0.6706
21.7
10 years 0.67
Extreme 0.6706
135.5
Manager TitleAgeSince
Chief Executive Officer 46 2023-04-30
Chief Operating Officer 36 2023-11-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 46 2018-10-16
Chairman 65 2022-05-23
Director/Board Member 62 2019-08-05
Date Insider Type Main position Quantity % Market Cap.
11/17/25 Free

Chairman

221,741 1.7138%
11/17/25 Free

Director

221,741 1.7138%
11/17/25 Free

Director

221,741 1.7138%
Change 5-day change 1-year change 3-year change Capi.($)
+0.89%-7.38%-16.30%-79.49% 18.84M
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+411.96%+495.33% 39.87B
-1.16%+12.96%+28.81%+7.25% 38.68B
-1.88%-3.03%+5.69%+53.00% 35.13B
-1.74%+5.12%+14.44%+41.77% 29.79B
-0.21%-4.04%+36.40%+125.75% 16.11B
-2.85%-3.92% - - 16.08B
-0.64%+2.65%+3.40%+13.11% 13.61B
-1.19%-1.32%-1.73%-34.37% 12.62B
Average -1.26%+0.21%+53.44%+70.40% 25.04B
Weighted average by Cap. -1.60%+2.03%+79.77%+108.60%

Financials

2026 *2027 *
Net sales 2.83M 2.46M 2.29M 2.1M 3.97M 270M 4.03M 26.99M 10.59M 135M 10.63M 10.4M 451M 20.09M 17.46M 16.25M 14.92M 28.18M 1.92B 28.61M 192M 75.18M 955M 75.43M 73.78M 3.2B
Net income -19.36M -16.83M -15.67M -14.38M -27.16M -1.85B -27.58M -185M -72.47M -920M -72.71M -71.12M -3.09B -19.89M -17.29M -16.09M -14.78M -27.91M -1.9B -28.34M -190M -74.46M -945M -74.71M -73.06M -3.17B
Net Debt - -
Logo Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Employees
5
Date Price Change Volume
26-07-31 US$1.130 +0.89% 37,439
26-07-30 US$1.120 +0.90% 72,944
26-07-29 US$1.110 -5.93% 39,225
26-07-28 US$1.180 -3.28% 20,200
26-07-27 US$1.220 -.--% 42,255
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.130USD
Average target price
7.867USD
Spread / Average Target
+596.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRKR Stock